Publications

Year Published

Type

Biomarker

Tumor Type

Meeting Type

With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

Treatment Choices Based on Multiplatform Profiling Platform, Unlike Those With Sequencing Alone, Do Not Cause a Cost Explosion in Refractory Cancer Patients
Multiplatform Tumor Profiling Delivers Value Bases Health Care in Refractory Cancer Patients
Comparison of Utility Cost in Three Commercially Available Precision Medicine Approaches in Oncology
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
Molecular profiles of small cell bladder and prostate cancer, comparisons with small cell lung cancer
A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)
Validation of a Microsatellite Instability Assay by NGS
Molecular Characterization of Intestinal and Diffuse Types of Gastric Cancer
Differences in Molecular Profiles of Males and Females with Colorectal Cancer (CRC)
Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas
Composition of the immune microenvironment differs between carcinomas
Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas
Distribution of microsatellite instability (MSI), tumor mutational load (TML) and PD-L1 status in molecularly profiled invasive breast cancer
Comparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy-
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy